Sclerostin (SOST): Osteocyte-Derived Wnt Inhibitor Regulating Bone Formation and the Target of Romosozumab in Research

# Sclerostin (SOST): Osteocyte-Derived Wnt Inhibitor Regulating Bone Formation and the Target of Romosozumab in Research

Introduction

Bone mass is continuously regulated through the coupled processes of formation by osteoblasts and resorption by osteoclasts. For decades, therapies targeting osteoporosis focused almost exclusively on anti-resorptive agents. The discovery that osteocytes — the terminally differentiated bone cells embedded within mineralized matrix — actively suppress bone formation through secretion of the protein sclerostin transformed our understanding and opened entirely new anabolic treatment avenues.

Sclerostin, encoded by the SOST gene, is a glycoprotein belonging to the DAN family of bone morphogenetic protein (BMP) antagonists. Its primary mechanism is inhibition of the canonical Wnt/β-catenin signaling pathway by binding to the low-density lipoprotein receptor-related proteins LRP5 and LRP6. When sclerostin occupies these co-receptors, it prevents the Wnt-induced receptor complex formation necessary to stabilize β-catenin and drive osteoblast differentiation and activity.

The clinical importance of this pathway crystallized when romosozumab, a monoclonal antibody neutralizing sclerostin, demonstrated unprecedented dual anabolic-antiresorptive effects — simultaneously increasing bone formation markers while decreasing bone resorption markers — and received FDA approval in April 2019 for postmenopausal osteoporosis at high fracture risk. Sclerostin biology now sits at the intersection of basic skeletal biology, mechanosensation research, and translational medicine.

Discovery: Sclerosteosis and Van Buchem Disease

The story of sclerostin begins not in a laboratory but in two rare human skeletal dysplasias characterized by dramatically increased bone density.

Sclerosteosis is an autosomal recessive condition first described in South African Afrikaaner populations and later elsewhere. Patients develop progressive bone overgrowth, particularly of the skull and jaw, along with syndactyly and cranial nerve entrapment due to bony encroachment on foramina. Despite these complications, the bone itself is mechanically robust — patients rarely suffer fragility fractures.

In 2001, two independent groups mapped sclerosteosis to loss-of-function mutations in a gene on chromosome 17q12-q21, which they named SOST (Brunkow et al., 2001, American Journal of Human Genetics,; Balemans et al., 2001, Human Molecular Genetics,). The protein product, sclerostin, was absent in affected individuals.

Van Buchem disease (hyperostosis corticalis generalisata) presents with similar though generally milder bone overgrowth. Unlike sclerosteosis, most Van Buchem patients have intact SOST coding sequences. Genome mapping revealed they instead harbor a 52-kb deletion approximately 35 kb downstream of the SOST coding region (Staehling-Hampton et al., 2002). This deletion removes an osteocyte-specific enhancer element — termed the ECR5 (evolutionarily conserved region 5) enhancer — essential for SOST transcription in bone. Van Buchem patients have undetectable or severely reduced sclerostin despite normal gene structure, demonstrating the regulatory importance of this enhancer.

The logical inference from both conditions was powerful: without sclerostin, bone accumulates. Sclerostin therefore functions as a physiological brake on bone formation. Inhibiting sclerostin should release this brake and increase bone mass — the founding hypothesis of romosozumab development.

Gene Structure and Protein Biochemistry

The SOST gene (chromosome 17q21.31) consists of two exons encoding a 213-amino-acid precursor protein that is processed to a mature 190-amino-acid secreted glycoprotein. The protein has a molecular weight of approximately 24 kDa (unglycosylated) to 32 kDa (glycosylated).

Sclerostin belongs to the DAN/CERBERUS family of cystine-knot-containing proteins, which also includes USAG-1/WISE, PRDC, and DAND5. The defining structural feature is the cystine-knot motif: three disulfide bonds formed by six conserved cysteines create a compact, stable fold. Embedded within this scaffold is a flexible "loop 2" region (also called the "thumb" in structural analyses) that directly contacts LRP5/6 and mediates Wnt pathway inhibition.

The functional interaction surface was defined structurally by Holdsworth et al. (2012, Journal of Biological Chemistry,), who showed that sclerostin contacts the first β-propeller domain (E1) of LRP6 at the same binding site as Wnt ligands and other inhibitors including Dkk1. This competitive occupancy of the LRP5/6 E1 site underpins the Wnt inhibitory activity.

Key glycosylation sites (N-linked at N85 and N95) contribute to protein stability and secretion efficiency but are not required for LRP5/6 binding activity per se.

The Wnt/β-Catenin Signaling Pathway and Sclerostin's Place in It

Canonical Wnt Signaling

The canonical (β-catenin-dependent) Wnt pathway controls cell fate, proliferation, and survival across virtually all metazoans. In bone, it is essential for osteoblast differentiation, activity, and survival. The core mechanism:

Without Wnt ("OFF" state): A cytoplasmic destruction complex — containing APC, Axin, GSK-3β, and CK1 — constitutively phosphorylates β-catenin, targeting it for ubiquitin-mediated proteasomal degradation. Nuclear β-catenin levels remain low, and TCF/LEF transcription factors maintain gene repression.

With Wnt ("ON" state): Wnt ligands (e.g., Wnt3a, Wnt10b) bind Frizzled receptors and simultaneously engage LRP5/6 as co-receptors, inducing phosphorylation of the LRP5/6 cytoplasmic tail by CK1 and GSK-3β. This phosphorylation recruits Axin to the membrane, disassembling the destruction complex. β-catenin accumulates, translocates to the nucleus, and activates TCF/LEF target genes including RUNX2, Osterix, Cyclin D1, and WISP1 — driving osteoblast differentiation and proliferation.

Sclerostin Mechanism

Sclerostin acts extracellularly by binding to LRP5 and LRP6 at their first β-propeller/EGF-like (E1) domains, physically blocking Wnt ligand co-receptor engagement. Without functional LRP5/6, the Wnt "ON" signal cannot be transduced, β-catenin remains degraded, and osteoblast activity is suppressed.

Importantly, sclerostin competes with Wnt ligands but does not directly bind Wnt proteins themselves. It also differs from another LRP5/6 inhibitor, Dkk1, in that sclerostin binds the E1 domain while Dkk1 preferentially binds the third β-propeller/EGF (E3) domain — though E1 is a shared binding site.

Osteocyte-Specific Expression

Sclerostin expression is remarkably restricted to osteocytes in mature bone. Osteoblasts and osteoclasts do not significantly express SOST under normal conditions. Osteocytes are the most abundant bone cells (~90-95% of all bone cells), residing in lacunae within the mineralized matrix and connected to each other and to surface cells via canalicular networks containing cytoplasmic processes.

This strategic positioning makes osteocytes ideal mechano-sensors: deformation of the canalicular fluid upon loading inhibits SOST expression (reducing sclerostin), releasing the Wnt brake and stimulating osteoblast activity — a molecular mechanism coupling mechanical loading to bone formation. Conversely, disuse (bed rest, space flight) dramatically increases sclerostin secretion, accelerating bone loss.

Regulation of Sclerostin Expression

Mechanical Loading

The most potent acute suppressor of SOST/sclerostin is mechanical strain. Hindlimb unloading in rodents increases SOST mRNA within 3-7 days; reloading reverses this within days. Human bed-rest studies show 40-60% increases in serum sclerostin within 2 weeks of immobilization (Robling et al., 2008, Journal of Biological Chemistry, PMID 18089564).

PTH and Intermittent Anabolic Therapy

Intermittent parathyroid hormone (PTH/teriparatide) suppresses sclerostin in osteocytes — partly explaining PTH's anabolic actions. PTH signaling through PKA activates HDAC4/5 nuclear export, relieving their suppression of MEF2C, which directly represses the SOST ECR5 enhancer.

Prostaglandin E2 (PGE2)

PGE2, released during bone loading, suppresses SOST via EP2/EP4 receptors and cAMP/PKA signaling, reinforcing load-driven bone formation.

Glucocorticoids

Glucocorticoid excess (endogenous Cushing's syndrome or pharmacological) dramatically increases sclerostin expression — a significant mechanism in glucocorticoid-induced osteoporosis.

TNF-α and Inflammatory Cytokines

Inflammatory conditions increase sclerostin, contributing to bone loss in rheumatoid arthritis, inflammatory bowel disease, and HIV infection.

Estrogen

Estrogen suppresses SOST expression; estrogen deficiency after menopause increases sclerostin, contributing to postmenopausal bone loss.

Calcium-Sensing Receptor / PTHrP

Sclerostin participates in feedback loops with calcium-sensing mechanisms, though details remain under investigation.

Sclerostin and Bone Remodeling: Beyond Simple Wnt Inhibition

Effects on Osteoclasts via OPG/RANKL

While sclerostin primarily targets osteoblast activity, Wnt signaling in osteoblasts also controls the OPG/RANKL ratio (osteoprotegerin/receptor activator of NF-κB ligand). Active Wnt signaling increases OPG (osteoclast inhibitor) and may decrease RANKL (osteoclast activator). Sclerostin, by suppressing Wnt, thus indirectly tips the balance toward osteoclast activity — explaining why sclerostin neutralization reduces bone resorption markers in addition to increasing formation markers.

This dual effect (increased formation + decreased resorption) is the mechanistic basis for the "uncoupling" observed with romosozumab in clinical trials — an extraordinary feature not seen with either pure anabolic agents (teriparatide increases resorption as well) or anti-resorptives.

Interactions with BMP Signaling

Sclerostin also has BMP antagonist activity (its DAN family membership reflects this), binding BMP2, BMP4, and BMP6. However, the relative contribution of BMP antagonism vs. LRP5/6 antagonism to its in vivo effects on bone remains debated. Most evidence from LRP5/6-binding mutants suggests the Wnt pathway is the dominant mechanism in bone.

Role in Cortical vs. Trabecular Bone

Sclerostin preferentially affects cortical bone formation (periosteal apposition), which is enriched in osteocytes relative to trabecular bone. Romosozumab's clinical effects show large increases in cortical bone density, particularly at the hip — a key advantage since cortical bone provides most of the mechanical strength in non-vertebral (hip, wrist) fractures.

Serum Sclerostin as a Biomarker

Circulating sclerostin can be quantified by ELISA and reflects osteocyte activity/abundance. Reference ranges vary by assay but generally fall in the 20-80 pmol/L range in adults.

Conditions elevating serum sclerostin:

• •Aging (sclerostin increases progressively with age)
• •Male sex (higher than females at any age)
• •Obesity (fat mass positively correlates)
• •Type 2 diabetes
• •Glucocorticoid excess
• •Chronic kidney disease (impaired renal clearance contributes)
• •Hypogonadism

Conditions lowering serum sclerostin:

• •Mechanical exercise (especially high-impact loading)
• •PTH/teriparatide therapy
• •Estrogen (though post-menopausal data are complex)
• •Osteogenesis imperfecta (fewer functional osteocytes)
• •Hypophosphatasia (alkaline phosphatase deficiency)

Serum sclerostin has been evaluated as a predictor of fracture risk and treatment response, with some prospective cohort data supporting its utility, though it is not yet a standard clinical test.

Genetic Studies: LRP5 and the Wnt Pathway in Human Bone Density

The importance of the Wnt/LRP5/6 pathway in bone mass was actually established before the sclerostin story was complete. Gain-of-function mutations in LRP5 (G171V and others) cause the High Bone Mass (HBM) syndrome — patients with extraordinary bone density and no fragility fractures, resistant to sclerostin binding. Loss-of-function LRP5 mutations cause Osteoporosis-Pseudoglioma syndrome (OMIM 259770), with severe osteoporosis.

These human genetic findings independently validated that sclerostin's target pathway — LRP5/6-dependent Wnt signaling — is a major determinant of human bone mass, giving mechanistic confidence to anti-sclerostin therapy development.

Romosozumab: From Biology to FDA Approval

Preclinical Development

Amgen and UCB co-developed romosozumab (AMG785/CDP7851), a humanized IgG2 monoclonal antibody targeting sclerostin. Murine preclinical studies showed dramatic increases in bone formation rate, bone mineral density, and bone strength after sclerostin neutralization (Li et al., 2009, Journal of Bone and Mineral Research, PMID 18767929).

Non-human primate studies confirmed substantial increases in BMD (+80% at the lumbar spine in some protocols) with no safety signals beyond the expected on-target effects on bone.

Phase III: FRAME Trial

The pivotal FRAME trial (Cosman et al., 2016, New England Journal of Medicine, PMID 27641143) enrolled 7,180 postmenopausal women with osteoporosis, randomizing them to romosozumab 210 mg SC monthly or placebo for 12 months, followed by denosumab in both groups for 12 additional months.

Key results at 12 months:

• •Vertebral fracture reduction: 73% relative risk reduction vs. placebo (primary endpoint)
• •Bone mineral density: +13.3% at lumbar spine, +6.9% at total hip vs. placebo
• •Bone formation markers (P1NP): Increased ~+145% at month 1, returning toward baseline by month 12
• •Bone resorption markers (CTX): Decreased ~-50% at month 1 — the "uncoupling" effect

The transition to denosumab maintained gains, supporting a "treat-to-target" strategy.

ARCH Trial: Active Comparator vs. Alendronate

The ARCH trial (Saag et al., 2017, New England Journal of Medicine,) compared romosozumab → alendronate vs. alendronate alone in high-risk postmenopausal women (prior vertebral fracture).

Romosozumab → alendronate reduced:

• •Clinical fractures by 27% vs. alendronate alone
• •Vertebral fractures by 48%
• •Non-vertebral fractures by 19%

However, ARCH also revealed a safety signal: a higher rate of serious cardiovascular events (adjudicated MACE: myocardial infarction, stroke, cardiovascular death) in the romosozumab arm (2.5% vs. 1.9%, p=0.04). This resulted in an FDA Black Box Warning on the romosozumab label, contraindicating use within 12 months of MI or stroke.

The cardiovascular mechanism is not established. Hypotheses include sclerostin's potential protective role in vascular calcification (sclerostin is expressed in vascular smooth muscle cells and may inhibit calcification), or the ARCH population's pre-existing high cardiovascular risk making the imbalance apparent. The FRAME trial, which excluded highest-risk cardiovascular patients, did not show a significant cardiovascular signal.

FDA Approval (April 2019)

Romosozumab (brand name: Evenity) received FDA approval in April 2019 for treatment of osteoporosis in postmenopausal women at high risk for fracture, with the cardiovascular Black Box Warning. The recommended regimen is 210 mg SC monthly for 12 months only — after which patients transition to an antiresorptive agent to maintain gains.

Other Conditions with Dysregulated Sclerostin

Glucocorticoid-Induced Osteoporosis (GIOP)

Animal studies show romosozumab is highly effective in GIOP models; clinical trials are exploring its use in glucocorticoid-treated patients with inflammatory diseases.

Male Osteoporosis

A Phase III trial (BRIDGE trial) in men with osteoporosis showed BMD increases comparable to those in women, supporting potential use in this underserved population.

Osteogenesis Imperfecta (OI)

Despite the logic of using a bone anabolic in OI, results have been complex — some OI subtypes may lack sufficient osteocytes to upregulate sclerostin meaningfully, limiting the therapeutic window.

Fracture Healing

Sclerostin is transiently elevated at fracture sites early in healing, then suppressed during the bone formation phase. Anti-sclerostin antibodies have been tested in preclinical fracture healing models with generally positive results; clinical studies are ongoing.

Cancer Metastasis to Bone

Multiple myeloma cells and some solid tumor metastases (breast, prostate) increase SOST expression in nearby osteocytes, creating local Wnt suppression that favors osteolytic lesion formation. Anti-sclerostin approaches are being explored in oncologic bone disease.

Diabetes-Associated Bone Fragility

Type 2 diabetes is paradoxically associated with normal-to-high BMD but increased fracture risk — "dysregulated bone quality." Elevated sclerostin in diabetic osteocytes is one proposed mechanism, with reduced bone formation rate despite high BMD creating porosity and impaired material properties.

Research Tools and Models

Current Research Frontiers

Skeletal Mechanotransduction Circuitry

The molecular pathway from osteocyte mechanical strain → SOST suppression → osteoblast activation is being mapped in detail. Key intermediates include primary cilia (mechanosensing organelles), NO/PGE2 release, Cx43 gap junctions between osteocytes, and Piezo1/2 mechanosensitive channels. Understanding these circuits could identify ways to mimic exercise-induced sclerostin suppression pharmacologically.

Sclerostin in Vascular Biology

Sclerostin is expressed in vascular smooth muscle cells (VSMCs) and is present in calcified atherosclerotic plaques. It may have a protective role against VSMC calcification by inhibiting Wnt-driven osteoblastic transdifferentiation of VSMCs. The cardiovascular safety signal with romosozumab has stimulated investigation into this potential vascular function.

Sequential Anabolic-Antiresorptive Strategies

The 12-month romosozumab window followed by antiresorptive consolidation has sparked interest in optimal sequencing: romosozumab → denosumab → romosozumab cycles, or romosozumab → bisphosphonate vs. romosozumab → denosumab comparisons. Data from extension studies are being analyzed.

Dual Inhibition: Sclerostin + Dkk1

Since sclerostin and Dkk1 both inhibit LRP5/6 through overlapping but distinct mechanisms, preclinical studies have tested simultaneous neutralization with bispecific antibodies. Results suggest additive bone anabolic effects — a potential avenue for patients with severe osteoporosis.

Crosstalk with FGF23 and Phosphate Metabolism

Sclerostin and FGF23 are both osteocyte-derived regulators. Sclerostin-deficient mice show elevated FGF23 and mild hypophosphatemia, suggesting regulatory crosstalk. The mechanistic basis and clinical relevance are under investigation, particularly in CKD where both are dysregulated.

Musculoskeletal Interactions

Sclerostin inhibits Wnt signaling not only in bone but potentially in adjacent muscle and tendon. Whether sclerostin contributes to muscle-bone unit dysfunction in sarcopenia/osteoporosis is being explored.

Conclusion

Sclerostin represents one of the most therapeutically successful targets to emerge from the study of rare skeletal dysplasias. The logical arc — from sclerosteosis/Van Buchem patients with extraordinary bone density → identification of SOST as the defective gene → understanding sclerostin as a Wnt pathway brake via LRP5/6 → romosozumab FDA approval — exemplifies bench-to-bedside translation at its most direct.

For researchers, sclerostin offers a window into osteocyte biology, skeletal mechanosensation, and the integration of bone mass with systemic metabolic signals including PTH, estrogen, and glucocorticoids. The ongoing investigation of its vascular roles adds complexity and clinical significance beyond the skeleton.

Romosozumab's remarkable anabolic-antiresorptive uncoupling — a pharmacological feat previously impossible — validates the concept of targeting the Wnt pathway checkpoint in bone. Future directions include combination approaches, extended cycling, and potential applications in diabetes-associated bone fragility, male osteoporosis, and cancer-related bone disease.

Key Research Citations

3. Uitterlinden AG, et al. (2002). Relation of alleles of the collagen type Ialpha1 gene to bone density and risk of osteoporotic fractures. New England Journal of Medicine, 338, 1016-1021. [LRP5 HBM context; Boyden EA et al. 2002 NEJM PMID 11997152 for LRP5 G171V]

4. Li X, et al. (2009). Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 24(4), 578-588. PMID: 18767929

6. Robling AG, et al. (2008). Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. Journal of Biological Chemistry, 283(9), 5866-5875. PMID: 18089564

7. Cosman F, et al. (2016). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 375(16), 1532-1543. PMID: 27641143

10. Baron R & Kneissel M (2013). WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nature Medicine, 19(2), 179-192. PMID: 23389618

---

This article is intended for Research Use Only (RUO). Sclerostin research tools and related compounds described herein are not approved for human therapeutic use outside of specifically indicated clinical applications. All studies involving sclerostin modulation in animal or cellular models must comply with applicable institutional and regulatory guidelines. This content does not constitute medical advice.